Medicines for ALS

These are some of the medicines that are used to treat patients with ALS. This is not intended to be a comprehensive list or guide.

Edaravone-Radicut/Radicava
Edaravone (Radicut/Radicava)

A radical scavenger approved by the Japanese PMDA and in the American FDA for the treatment of ALS.

+Read more
Edaravone-generic
Edaravone generic

A generic version of edaravone, produced by several manufacturers. It is approved by the Japanese PMDA for the treatment of cerebral infarction.

+Read more
Ibudilast-Ketas
Ibudilast (Ketas)

It has an anti-inflammatory and neuroprotective effect on the brain. It has been granted orphan drug designation* for the treatment of ALS by the European EMA, and the American FDA.

+Read more
Tudcabil-Tudca
Tudcabil (Tudca)

A bile salt that is found naturally occurring in the body. It has been granted orphan designation* by the European Medicines Authority (EMA) for the treatment of ALS.

+Read more

More information about Amyotrophic Lateral Sclerosis (ALS)

Contact support

Have a question about a medicine or our service? Contact us. Our team of doctors and medical experts are on hand to answer any questions you might have.
Our team speak 17 different languages.

Send us a message

We will get back to you shortly during our working hours: 9:00 to 18:00 CET, Monday to Friday.

Thank you for your message !

We will get back to you shortly during our working hours: 9:00 to 18:00 CET, Monday to Friday.

Generic drugs are medicines created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. A generic medicine works in the same way and provides the same clinical benefit as its brand-name version.

* Orphan drugs are medicines targeting conditions which are so rare that they are unlikely to generate sufficient profit to justify research and development costs. Each regulatory agency (e.g. the FDA or EMA) has an independent process for assigning orphan drug status. Sponsors of these medicines receive incentives from the agencies to support and facilitate the development and authorisation of these therapeutics.

US 0